THE SCIENCE
The P-tau217 Blood Test: Redefining Early Alzheimer’s Detection
The Basics of Brain Health
Your brain’s health is shaped by a delicate balance of genetics, lifestyle, and age. Memory, focus, and decision-making all depend on how well your brain’s cells communicate and stay protected over time. When changes occur — whether from stress, aging, or disease — early detection becomes essential. That’s why understanding your cognitive function through reliable testing is the first step toward protecting it.
OF OLDER AMERICANS
living with mild cognitive impairment receive a diagnosis.
Alzheimer’s vs. Dementia
Symptoms of Alzheimer’s Disease
Progression
Causes of Alzheimer’s Disease
Early Detection Right at Home
Neurogen makes early Alzheimer’s detection accessible and precise. By combining a brief online cognitive assessment with an at-home p-tau217 blood test, we help individuals and families gain valuable insights into brain health, years before severe symptoms may appear. This seamless approach brings clinical-grade testing into the comfort of your home, turning proactive care into an empowering, everyday choice.
Revolutionary Testing Technology
P-tau217 is a key blood biomarker linked to Alzheimer’s disease that begins to change long before memory symptoms surface. Measuring p-tau217 through a simple blood test allows for earlier detection and ongoing monitoring of potential cognitive changes. Neurogen’s testing technology delivers clinical-quality accuracy from a small, at-home blood sample, offering insights comparable to advanced imaging methods like PET scans, but with greater convenience and at a fraction of the cost. It’s a breakthrough that brings the future of Alzheimer’s detection directly to you.
Our testing method is highly accurate, providing clinical quality results from an at-home blood sample.
This blood test performs as well as the current standard of care (PET-scans) at a fraction of the cost.
Early detection gives
you time to act
When Alzheimer's is detected early, you have more time to take proactive steps to better protect and care for your cognitive health.
One-of-a-Kind Testing and Exceptional Care
At Neurogen, we do more than deliver results — we partner with you to take control of brain health with confidence. Our innovative approach combines advanced p-tau217 testing with a comprehensive care ecosystem designed to support you from discovery to action.
Each step connects you with leading, board-certified neurologists and Alzheimer’s disease specialists who interpret your results, explain what they mean, and guide your next steps. From early detection through ongoing care, Neurogen provides clinical precision and compassionate support — ensuring you’re never alone on the path to protecting your memory health.
Led by scientists
Our leaders are experts in neurology, dementia care and life sciences innovation. Their mission is to ensure that more patients have access to the highest quality care.
Dr. Rany Aburashed
CEO & Founder
-
Over 15 years expertise in neurology and neuroimmunology, coupled with a proven track record of leadership in clinical care and healthcare systems.
-
Combines dedication to patient care as Chief Medical Officer of Insight Corporation with a commitment to advancing innovative diagnostic solutions for neurodegenerative diseases.
-
Has led numerous clinical trials, contributing to breakthroughs in the treatment of multiple sclerosis and related conditions.
-
Combines big-picture ambition with a focus on sustainable and effective solutions that improve lives and redefine the standards of patient care.
Elisabeth Thijssen, PhD
Chief Scientific Officer
-
Leads Neurogen’s scientific vision, leveraging over a decade of expertise in neurodegenerative research and biomarker innovation.
-
Her groundbreaking work on Alzheimer’s blood tests, featured in Nature Medicine and The Lancet Neurology, has redefined early detection of the disease.
-
Has led high-impact R&D and business initiatives across consulting and biotech, forging innovative solutions and strategic partnerships that drive meaningful impact.
-
Holds a Cum Laude PhD in Neurochemistry of Alzheimer's Disease, a Master's in Pharmaceutical Sciences, and a Bachelor's in Biomedical Sciences.
Kenneth Bahk, PhD
Chief Strategy Officer
-
Shapes Neurogen’s strategic vision, bringing decades of experience in healthcare innovation, investment, and ecosystem building.
-
Accomplishments include founding, building, and investing in transformative diagnostic and life science startups, achieving multiple market-leading exits.
-
Has driven impactful R&D, policy, and business initiatives with organizations including the White House, JP Morgan, the Mayo Clinic, as well as leading professional groups in laboratory medicine and innovation.
-
Holds an MS in Neurobiology, a PhD in Biochemistry and Molecular Biology, and an MBA from Northwestern University.
"The current landscape of Alzheimer's diagnosis remains reactionary and often a diagnosis is made quite late. This puts us at a massive disadvantage in addressing our modifiable risk factors, gaining access to disease-modifying therapies in time, and guidance towards cutting-edge clinical trials when patients remain clinically eligible. Our goal at Neurogen Biomarking is to close this gap and help guide patients into the broader ecosystem in the most clinically and scientifically accurate way at a significantly earlier time."
- Dr. Rany Aburashed
1 What is Alzheimer's Disease? Alzheimer's Association. https://www.alz.org/alzheimers-dementia/what-is-alzheimers
2 Mild Cognitive Impairment (MCI) Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/mild-cognitive-impairment/symptoms-causes/syc-20354578
3 Alzheimer's Disease, Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447
4 Stages of Alzheimer's. Alzheimer's Association. https://www.alz.org/alzheimers-dementia/stages
5 Dhana K, et al. Healthy lifestyle and the risk of Alzheimer's dementia: Findings from two longitudinal studies. Neurology. 2020; 95:1-10. doi: 10>1212/WNL. 0000000000009816
6 Preventing Alzheimer's Disease: What Do We Know? National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-and-dementia/preventing-alzheimers-disease-what-do-we-know
7 Mielke (2024) Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease.
8 McDade (2022) - Clinical Trial Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
9 Pontecorvo (2022) - JAMA Neurol. 2022;79(12):1250-1259. doi:10.1001/jamaneurol.2022.3392
10 Cummings (2024) - Alzheimer's disease drug development pipeline: 2024